Navigation Links
U.S. Pharmaceutical Budget and Staffing: Powerful New Metrics-Based Study
Date:5/7/2008

CHAPEL HILL, N.C., May 7 /PRNewswire/ -- In today's marketplace, pharmaceutical and biotechnology companies are experiencing intense pricing, political, regulatory and market pressures. These forces are creating stress on the industry's fundamental business model. Consequently, pharmaceutical and biotechnology companies must evaluate the optimal levels of human and capital investment in the commercial enterprise to ensure health and competitiveness.

Due to increasing prices and shrinking margin pressures, few, if any, companies can ignore how many people they staff to critical functions. Best Practices, LLC's benchmarking study analyzes resource allocation specific to key business functions in the pharmaceutical and biotechnology industries and can further assist business unit managers in assessing their level of staffing investment and resources channeled into different business functions.

A sample of analyzed functions in the report is:

-- Marketing -- this is further segmented, analyzed, and benchmarked on

the basis of product

-- State Government Affairs -- benchmarking data segmented by sales

revenues provide greater insight and highlights trends

-- Finance -- segmented and benchmarked by sales revenues to provide

greater insight and trends

If you have to defend or validate budget and staffing resource decisions, the Best Practices Pharmaceutical Budget and Staffing Benchmark Guide will prove invaluable. The rich metrics contained in this comprehensive report emanate from survey responses from staffing executives at such elite pharmaceutical and biotech companies as Abbott Labs, AstraZeneca, Bristol-Myers Squibb, J&J, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche and Sanofi-Aventis.

To download a free excerpt of U.S. Pharmaceutical Budget and Staffing Excellence visit http://www3.best-in-class.com/rr941.htm and for more information, contact Cameron Tew at 919-767-9246 or at ctew@best-in-class.com

BEST PRACTICES, LLC is a benchmarking and consulting firm that conducts work based on the principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more information, call (919) 403-0251 or visit http://www.best-in-class.com .


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  Caris Life Sciences, ... Lustgarten Foundation, the largest private funder of pancreatic ... trial evaluating the impact of immunotherapy in the ... trial enrollment services to identify potential trial candidates ... between treating physicians and study investigators. The Lustgarten ...
(Date:1/18/2017)...  Market Research Future published a half-cooked research report on Global ... at a CAGR of 12% during the period 2016 to 2022. ... ... cell division without any control. These abnormal cells have the ability ... cells can spread to other parts of the body through the ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... Balance™ GT soybeans. The new Balance™ GT Soybean Performance System will combine industry-leading ... isoxaflutole, the active ingredient in the new Balance® Bean herbicide. The Balance™ GT ...
(Date:1/17/2017)... 17, 2017  An international team of researchers ... St. Boniface Hospital Albrechtsen Research Centre/University of Manitoba ... unmet health need affecting nearly one in 15 ... Investigation, their results identify small molecule drugs with ... neuronal injury in animal models of metabolic, chemical ...
Breaking Biology Technology:
(Date:1/18/2017)... MedNet Solutions , an innovative ... spectrum of clinical research, is proud to announce ... the organization in terms of corporate growth, outside ... and services. The company,s exceptional achievements can be ... iMedNet ™ – MedNet,s ...
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Forecasts, 2015 - 2022," projects that the global biometric technology market is expected to ... 2016 to 2022. Continue Reading ... ...      ...
(Date:1/6/2017)... 5, 2017  SomaLogic announced today that it ... established by iCarbonX, the China ... "Global Digital Health Ecosystem that can define each ... individual,s biological, behavioral and psychological data, the Internet ... companies, SomaLogic will provide proteomics data and applications ...
Breaking Biology News(10 mins):